Innospec (NASDAQ:IOSP) Stock Rating Lowered by ValuEngine

ValuEngine downgraded shares of Innospec (NASDAQ:IOSP) from a buy rating to a hold rating in a research report sent to investors on Thursday, ValuEngine reports.

Several other equities research analysts have also recently weighed in on IOSP. Zacks Investment Research cut shares of Innospec from a buy rating to a hold rating in a research note on Saturday, July 13th. BidaskClub cut shares of Innospec from a strong-buy rating to a buy rating in a research note on Friday, July 12th.

Shares of NASDAQ IOSP traded down $3.96 during mid-day trading on Thursday, hitting $86.41. The company had a trading volume of 2,892 shares, compared to its average volume of 90,074. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 2.28. The firm’s 50-day moving average price is $90.67. Innospec has a 12 month low of $53.07 and a 12 month high of $96.23. The company has a market cap of $2.21 billion, a price-to-earnings ratio of 18.15 and a beta of 1.29.

Innospec (NASDAQ:IOSP) last released its earnings results on Tuesday, May 7th. The specialty chemicals company reported $1.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.07. Innospec had a net margin of 6.08% and a return on equity of 14.92%. The business had revenue of $388.30 million during the quarter. During the same quarter in the previous year, the business posted $1.02 EPS. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. Analysts anticipate that Innospec will post 5.15 EPS for the current fiscal year.

In other Innospec news, VP Brian Watt sold 2,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $82.01, for a total transaction of $164,020.00. Following the completion of the transaction, the vice president now owns 30,992 shares in the company, valued at $2,541,653.92. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 4,300 shares of company stock valued at $356,236. Corporate insiders own 1.62% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in IOSP. Avestar Capital LLC bought a new position in shares of Innospec in the first quarter valued at approximately $66,000. Meeder Asset Management Inc. raised its stake in shares of Innospec by 94.0% in the second quarter. Meeder Asset Management Inc. now owns 943 shares of the specialty chemicals company’s stock valued at $86,000 after acquiring an additional 457 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Innospec in the second quarter valued at approximately $108,000. Grandfield & Dodd LLC bought a new position in shares of Innospec in the first quarter valued at approximately $200,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Innospec in the second quarter valued at approximately $201,000. Hedge funds and other institutional investors own 93.25% of the company’s stock.

About Innospec

Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals worldwide. It operates through four segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives. The Fuel Specialties segment offers a range of specialty chemical products used as additives in various fuels.

Featured Story: Discover Your Risk Tolerance

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.